Validating the biological origin of in vivo fractional intracellular volume from VERDICT-MRI in the prostate
Abstract Objective Noninvasive microstructure estimates using magnetic resonance imaging (MRI) show potential in improving prostate cancer (PCa) diagnosis; however, histological validation is necessary. Materials and methods We used data from the Histo-MRI trial (NCT04792138). Participants with biopsy-confirmed PCa underwent multiparametric (mp) MRI and “vascular, extracellular, and restricted diffusion for cytometry in tumors” (VERDICT)-MRI before radical prostatectomy. Personalized molds enabled matching prostatectomy histology with corresponding VERDICT-MRI images. Comparisons between histological epithelial cell density measures and MRI were made on a region-of-interest (ROI) basis using Pearson correlation coefficient ( r ) with 95% confidence interval (CI). Differences between benign tissue and clinically significant PCa were analyzed using the area under the receiver operating characteristic curve (AUC). Results Fifty-two participants, aged 65 ± 6 years (mean ± standard deviation), with Gleason grade ≥ 3 + 4, were included. ROI analysis showed stronger correlations of VERDICT fractional intracellular volume (fIC) with epithelial fraction, epithelial cell density, and cell density ( r = 0.784 [0.70, 0.84], 0.747 [0.66, 0.81], 0.711 [0.60, 0.79] than VERDICT ADC ( r = -0.639 [-0.54, -0.71], -0.609 [-0.51, -0.69], -0.587 [-0.45, -0.69]), or mpMRI ADC ( r = -0.357 [-0.18, -0.51], -0.315 [-0.15, -0.46], -0.266 [-0.08, -0.43]), respectively ( p < 0.001). VERDICT fIC showed similar differences between benign and clinically significant PCa (0.16 ± 0.10 to 0.51 ± 0.13, AUC = 0.99, p < 0.001) to epithelial fraction (0.21 ± 0.08 to 0.43 ± 0.12, AUC = 0.94, p < 0.001). Conclusion VERDICT fIC showed clinical potential as a biomarker of epithelial cell density. Key Points Question Can VERDICT-MRI fIC provide a biologically interpretable, noninvasive imaging biomarker of epithelial cell density in the prostate? Findings VERDICT fIC showed stronger correlations with histological epithelial fraction, cell density, and epithelial density than both VERDICT-derived ADC and mpMRI ADC. Relevance statement These findings support in vivo VERDICT fIC as a noninvasive biomarker of prostate epithelial microstructure and show promise for wider clinical use, improving the detection rate of clinically significant PCa, reducing unnecessary biopsies, and allowing better risk stratification.
Authors
- Eleftheria Panagiotaki (ORCID: https://orcid.org/0000-0002-2697-3447)
- Caroline M. Moore (ORCID: https://orcid.org/0000-0003-0202-7912)
- Adam Retter (ORCID: https://orcid.org/0000-0003-3712-0965)
- Thomas Parry
- Francesco Grussu (ORCID: https://orcid.org/0000-0002-0945-3909)
- Veeru Kasivisvanathan (ORCID: https://orcid.org/0000-0002-0832-382X)
- Lucy Caselton
- Dominic Patel (ORCID: https://orcid.org/0000-0001-9223-6632)
- Thomy Mertzanidou (ORCID: https://orcid.org/0000-0001-9706-7399)
- Adam Phipps
- Joey Clemente
- Marta Masramon
- Alistair Grey
- Marianti-Vasiliki Papoutsaki
- Shonit Punwani
- Lorna Smith
- Alex Freeman
- Eoin Dinneen
- Natasha Thorley
- Manju Mathew
- David Atkinson
- Aiman Haider
- Saurabh Singh
- Greg Shaw
- Daniel C. Alexander
Institutions
- University College Hospital (GB)
- Barts Health NHS Trust (GB)
- Global Strategy Group (US)
- Hawkeye Community College (US)
- Cancer Research UK (GB)
- UCL Biomedical Research Centre (GB)
- Vall d'Hebron Institute of Oncology (ES)
- University College London (GB)
Publication Details
- Journal
- European Radiology Experimental
- Published
- 2026-09-09
- DOI
- https://doi.org/10.1186/s41747-026-00797-w
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00